New law requires dementia-specific training for assisted living staff
By
Amy Novotney
Jun 14, 2022
Colorado lawmakers recently passed legislation mandating dementia-specific training for professional caregivers in assisted living communities and some other long-term care settings.
Metformin displayed a lowest risk for dementia across diverse antidiabetics, while α-glucosidase inhibitors had the highest risk.
‘Substantial’ decline in dementia rates due in part to higher education levels: study
By
Kimberly Bonvissuto
Nov 08, 2022
The prevalence of dementia in older adults in the United States declined 30% between 2000 and 2016, possibly due to rising education levels, a reduction in smoking and better treatment of cardiovascular...
Older adults at risk for dementia see fast declines in household wealth before dementia onset
By
Kimberly Bonvissuto
Sep 19, 2023
Household wealth, especially financial wealth, declines much more quickly among people with probable dementia in the decade before dementia onset compared with older adults without a dementia diagnosis,...
2 ways to help residents combat dementia
Nov 19, 2015
Recently published research from the United States and Australian reveals two ways to slow or prevent cognitive decline.
15 percent of off-label antipsychotic use in assisted living may be inappropriate, but nursing home reduction...
By
Kimberly Bonvissuto
Sep 14, 2021
The rate of potentially inappropriate prescribing of drugs in assisted living is 15% for antipsychotics and 21% for antianxiety medications, according to the authors of a new study published in JAMDA,...
Inverse link found for antioxidant levels, all-cause dementia
May 04, 2022
Serum lutein+zeaxanthin and β-cryptoxanthin levels were inversely associated with incident all-cause dementia.
Retinal layer thickness linked to cognitive decline in older adults
May 27, 2022
Thinner baseline total macular retinal nerve fiber layer thickness was associated with a larger decline in cognitive function test scores during follow-up.
Cognitive impairment delayed with genetic variant
Jun 20, 2024
The onset of cognitive impairment was delayed among those heterozygous for the apolipoprotein E3 Christchurch variant.
Medicare spending would increase $2.0 to $5.1 billion with lecanemab
May 18, 2023
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636